The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patients.
Ten advanced cancer patients (both with hormone-sensitive and non-hormone sensitive tumors) were treated with high dose medroxyprogesterone acetate (MAP, greater than 500 mg/day). We determined body weight, lean body mass, blood pressure, sodium blood level, urinary excretion, and exchangeable sodium pool by the 22Na method before and after treatment. These data seem to exclude a fluid retentive effect for high-dose MAP.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001834:Body Water / Q000378:metabolism*; D004573:Electrolytes / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D017258:Medroxyprogesterone Acetate; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000970:Antineoplastic Agents; D004573:Electrolytes; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone